Clinical Trials
11
Trial Phases
4 Phases
Drug Approvals
4
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)β’ Click on a phase to view related trials
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 55
- Registration Number
- NCT06604442
- Locations
- πΊπΈ
Mayo Clinic, Jacksonville, Florida, United States
πΊπΈCity of Hope Medical Center, Duarte, California, United States
πΊπΈTower Urology, Los Angeles, California, United States
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 23
- Registration Number
- NCT04410367
- Locations
- πΊπΈ
John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California, United States
πΊπΈYale School of Medicine, New Haven, Connecticut, United States
πΊπΈMiami Cancer Institute, Miami, Florida, United States
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 151
- Registration Number
- NCT04410133
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈSt. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
πΊπΈUniversity of California, San Francisco, San Francisco, California, United States
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
- Conditions
- Prostate Cancer
- Interventions
- Drug: rhPSMA-7.3 (18F) InjectionDiagnostic Test: Positron emission tomography scan
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 391
- Registration Number
- NCT04186845
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈTower Urology, Los Angeles, California, United States
πΊπΈUniversity of California Irvine Medical Center (UCIMC), Orange, California, United States
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
- Conditions
- Prostate Cancer
- Interventions
- Drug: rhPSMA-7.3 (18F) InjectionDiagnostic Test: Positron Emission Tomography scan
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Blue Earth Diagnostics
- Target Recruit Count
- 356
- Registration Number
- NCT04186819
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈTower Urology, Los Angeles, California, United States
πΊπΈUniversity of California Irvine Medical Center (UCIMC), Orange, California, United States
- Prev
- 1
- 2
- Next
News
FDA Approves Posluma, First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer
The FDA has approved flotufolastat F 18 injection (Posluma) for PET imaging of PSMA-positive lesions in prostate cancer patients, aiding in metastasis detection and recurrence assessment.